Key facts
- It has raised $185.0M; the latest was Early Stage VC ($185.0M) in Nov 2025.
- Notable investors include Andreessen Horowitz, OrbiMed, Forbion, Frazier Healthcare Partners, Enavate Sciences — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Braveheart Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Braveheart Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Braveheart Bio
Developer of a cardiac myosin inhibitor intended for treating cardiovascular disorders. The company's drug features the ability to treat obstructive hypertrophic cardiomyopathy (oHCM) by reducing excessive heart muscle contraction, enabling the healthcare industry to develop medicines for progressive heart conditions.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 5
- Website
- braveheart.bio/
- Ownership
- Privately Held (backing)
Braveheart Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Braveheart Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Braveheart Bio in its N-PORT filings yet. We sweep new filings monthly.